Confronto

Glepaglutide vs. Sincalide

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Ricerca (altro)

N. CAS

nessun dato

25126-32-3

Peso molecolare

nessun dato

1143.29 g/mol

Emivita

nessun dato

Sequenza

nessun dato

Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2

Meccanismo d'azione

Glepaglutide

As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.

Sincalide

Sincalide activates CCK receptors, triggering gallbladder contraction and pancreatic enzyme secretion. This effect is used diagnostically to measure the gallbladder ejection fraction (e.g. in HIDA scintigraphy).

Base di evidenze

Evidenza più alta

RCT sull'uomo

Studio sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	Glepaglutide	Sincalide
Germania	Non approvato	Non chiaro
Stati Uniti	Non approvato	Su prescrizione

Voci complete

Frequently asked questions

What is the difference between Glepaglutide and Sincalide?: Glepaglutide is classified as "Ricerca (altro)", while Sincalide is classified as "Ricerca (altro)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Sincalide: Sincalide is the synthetic C-terminal octapeptide of the hormone cholecystokinin (CCK-8). As Kinevac it is FDA-approved to stimulate gallbladder contraction for diagnostic imaging. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Glepaglutide or Sincalide?: The highest available evidence level is "RCT sull'uomo" for Glepaglutide and "Studio sull'uomo" for Sincalide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Glepaglutide and Sincalide in Germany and the United States?: Germania: Glepaglutide — Non approvato, Sincalide — Non chiaro. Stati Uniti: Glepaglutide — Non approvato, Sincalide — Su prescrizione. These are factual summaries with source and review date on the individual pages.

Country

Glepaglutide

Sincalide

Germania

Non approvato

Non chiaro

Stati Uniti

Non approvato

Su prescrizione

Frequently asked questions

What is the difference between Glepaglutide and Sincalide?

Glepaglutide is classified as "Ricerca (altro)", while Sincalide is classified as "Ricerca (altro)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Sincalide: Sincalide is the synthetic C-terminal octapeptide of the hormone cholecystokinin (CCK-8). As Kinevac it is FDA-approved to stimulate gallbladder contraction for diagnostic imaging. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Glepaglutide or Sincalide?

The highest available evidence level is "RCT sull'uomo" for Glepaglutide and "Studio sull'uomo" for Sincalide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Glepaglutide and Sincalide in Germany and the United States?

Germania: Glepaglutide — Non approvato, Sincalide — Non chiaro. Stati Uniti: Glepaglutide — Non approvato, Sincalide — Su prescrizione. These are factual summaries with source and review date on the individual pages.